v3.22.2.2

Intangible Assets | 12 Months Ended
--- | ---
Jun. 30, 2022
Intangible Assets [Abstract] |
Intangible Assets | 12. Intangible Assets The Company has two categories of intangible assets – intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December 2003 from Fraunhofer USA Inc., acting through its Center for Molecular Biotechnology ("Fraunhofer"), pursuant to a Technology Transfer Agreement, as amended (the "TTA"). The Company designates such technology further developed and acquired from Fraunhofer as iBioLaunch™ or LicKM™ or FastPharming technology. The value on the Company’s books attributed to patents owned or controlled by the Company is based only on payments for services and fees related to the protection of the Company’s patent portfolio. The intellectual property also includes certain trademarks. On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 – Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T regulatory (T reg) cells while enhancing T effector (T eff) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. In addition, the Company also received preferred shares and an option for future collaboration licenses. In January 2014, the Company entered into a license agreement with the University of Pittsburgh whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology") which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone – filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") – initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021. On February 8, 2022, the Company signed another amendment to the license agreement with the University of Pittsburgh. The deadline for the next milestone was extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of 10 years and other intellectual property is amortized over a period from 16 to 23 years unless they were determined to have indefinite lives. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments are based on the excess of the carrying amount over the fair value of the assets. No impairments were recorded in Fiscal Year 2022. The Company recorded an impairment of licensed technology in the amount of $143,000 in Fiscal Year 2021. This amount was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. ​ The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, |  | June 30,
​ | ​ | 2022 | ​ | 2021
Intellectual property – gross carrying value | ​ | $ | 3,100 | ​ | $ | 3,100
Patents and licenses – gross carrying value | ​ |  | 2,846 | ​ |  | 2,720
​ | ​ |  | 5,946 | ​ |  | 5,820
Intellectual property – accumulated amortization | ​ |  | (2,867) | ​ |  | (2,711)
Patents and licenses – accumulated amortization | ​ |  | (2,403) | ​ |  | (2,157)
​ | ​ |  | (5,270) | ​ |  | (4,868)
Total definite lived intangible assets, net of accumulated amortization | ​ | ​ | 676 | ​ | ​ | 952
​ | ​ | ​ | ​ | ​ | ​ | ​
License - indefinite lived | ​ | ​ | 4,175 | ​ | ​ | —
​ | ​ | ​ | ​ | ​ | ​ | ​
Total net intangible assets | ​ | $ | 4,851 | ​ | $ | 952
​ Amortization expense was approximately $401,000 and $291,000 for the years ended June 30, 2022 and 2021, respectively. The weighted-average remaining life for intellectual property and patents at June 30, 2022 was approximately 1.5 years and 5.6 years, respectively. The estimated annual amortization expense for the next five years and thereafter is as follows (in thousands): ​ ​
​ | ​ | ​ | ​
​ | ​ | ​ | ​
For the Year Ending June 30, | ​ | ​ | ​
2023 | ​ | $ | 261
2024 | ​ | ​ | 165
2025 | ​ | ​ | 69
2026 | ​ | ​ | 57
2027 | ​ | ​ | 45
Thereafter | ​ | ​ | 79
​ | ​ | $ | 676
​ ​ ​

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI https://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration